Glaxosmithkline LLC

Smithkline Beecham Corporation

Other

Andrew Lamont Larkin

Rodolfo Cadilla

Philip Stewart Turnbull

David John Cowan

Eugene Lee Stewart

Istvan Kaldor

Jason Daniel Speake

Darryl Lynn McDougald

Amarjit Sab Randhawa

John Albert Ray

Huiquiang Zhou

Katherine Stetson

David Lee Musso

Michael Joseph Bishop

Paul Kenneth Spearing

Gary Martin Green

Cunyu Zhang

Jerzy Ryszard Szewczyk

Kevin Karl Barvian

Huiqiang Zhou

Darryl Lynn Mcdougald

Apparatus for an alarm clock with one or more alarms that are challenging to deactivate are provided. The alarm clock is fixedly attached to a wall or other surface, and contains a power source such that the alarm cannot be deactivated by unplugging the alarm clock or by easily removing batteries. The alarm(s) may be programmed to activate for a first length of time. To deactivate the alarm, a user must take some action to interact with the alarm clock, for a second length of time, which second length of time is sufficient for the user to become fully awake. Aspects of the alarm clock may be digital or analog, may have manual or electronic or remote controls, may have one or more alarms of different types, and may require different types of user interaction with alarm deactivation components in order to deactivate the one or more alarms.

Alarm clock with challenging alarm deactivation

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction

This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.

Chemical compounds

Compounds as antagonists or inverse agonists at opioid receptors

The present invention relates to novel compounds which are antagonist or inverse agonists at an opioid receptor. Such compounds are useful in the treatment of obesity and related diseases and/or conditions in mammals, particularly humans. Methods of making and using such compounds are also disclosed.

Heterocycle compounds

This invention relates to benzonitryl and nitrobenzyl derivatives that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds. These compounds are useful, for example, in the treatment or prophylaxis of conditions or disorders that respond to selective androgen receptor modulation.

Benzonitryl and nitrobenzyl derivatives that modulate androgen receptors

This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds.

Aniline derivatives as selective androgen receptor modulators

Growing community of inventors

Research Triangle Park, NC, United States of America

Andrew Lamont Larkin